March 2016

Dear shareholders and prospective shareholders,

During the month of March, CRH made significant progress in our US investor awareness program. Joining the six Canadian analysts that currently provide research coverage on CRH Medical, Canaccord Genuity (US) initiated coverage on the company as well. Not only does this add credibility when introducing our story to new investors in the US, it also provides an opportunity to further expand our capital markets presence and take full advantage of our NYSE listing.

Canadian and US Marketing

Management spent some time marketing to prospective institutional investors in New York in March. The combination of our operational execution in 2015 and our NYSE listing achieved in September has opened up a broader investment audience for us to engage. It will continue to be our focus to grow the investor base in the US throughout 2016.

I was able to spend several days this month in different markets in Ontario, meeting with prospective retail investors and presenting our story and growth plans in detail. It was a productive week, and it is always meaningful to introduce CRH to a new segment of the investment community.

GI Conferences

March proved to be a busy month for conferences, with CRH attending four meetings over the past several weeks. Earlier in the month, we attended both the ACG/LGS Regional Postgraduate Course held in New Orleans, LA and the Therapeutic Endoscopy Course held in Park City, UT. We have been regular attendees at both meetings for the past several years. As in the past, we were able to take part in the hands-on sessions that are part of the course in Park City, demonstrating the CRH O’Regan System to a number of new physicians interested in providing this continuum of care to their patients.

We then both exhibited and presented at the GI Roundtable meeting held in Fort Worth, Texas. This meeting brought together a number of prominent gastroenterologists and senior practice administrators to discuss various topics surrounding the future of gastroenterology. Over the course of the conference, we were afforded the opportunity to speak with many physicians about both the O’Regan System and CRH Anesthesia.

The end of the month had us attending the ACG/FGS Annual Spring Symposium in Bonita Springs, FL. This regional meeting was extremely successful in terms of new lead generation on both sides of the business and we look forward to working closely with these leads over the course of the next several months.

If you have any questions or would simply like a general update, don’t hesitate to contact me. Thank you for your continued support and we look forward to updating you again in a month’s time.

David Matousek
Director, Investor Relations
CRH Medical Corporation
T: 800.660.2153 x 1030
W: www.crhmedcorp.com
E: dmatousek@crhmedcorp.com

We're a stable, profitable company respected by both patients and physicians. Learn more »